To prevent Covid-19 or protect infected patients from severe forms of the disease, several treatments (antivirals, antiretrovirals or immunomodulators) have been developed or are under development. The French National Authority for Health has already authorized early access to two treatments: Ronapreve® and Evusheld®. This early access has also just been granted to Xevudy® (sotrovimab) developed by the GSK laboratory.
Xevudy® obtained marketing authorization from the European Medicines Agency (EMA) on December 17th. This drug has a double action: it prevents the virus from infecting new cells and it eliminates cells that are already infected.
Who is Xevudy intended for?
This monoclonal antibody is indicated for adults and adolescents aged 12 years and over (and weighing more than 40 kg) infected with SARS-CoV-2 who do not require oxygen supplementation and who are at risk of developing a severe form. of the disease.
Early access to medicines (a system which allows certain patients to benefit, on an exceptional and temporary basis, from certain medicines which have not yet received marketing authorisation) is currently reserved for people high risk:
patients aged 80 and over
patients with an immune deficiency related to a pathology or treatment
patients at risk of complications.
Positive Covid test before the booster dose: what to do?
No, tap water is not positive for Covid-19
Your Health Paris (06/01): It’s time for “Dry January”
COVID FIGURES. The results in France this Thursday, January 13 live: announcements, figures
Alcohol, tobacco and cannabis use down among college students